Raymond James Financial
CADL icon

Raymond James Financial’s Candel Therapeutics CADL Stock Holding History

Raymond James Financial’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$196K Buy
40,000
+7,000
+21% +$38.1K ﹤0.01% 4895
2025
Q4 		$186K Buy
33,000
+10,836
+49% +$58.3K ﹤0.01% 4810
2025
Q3 		$113K Hold
22,164
– – ﹤0.01% 4731
2025
Q2 		$112K Sell
22,164
-486
-2% -$2.5K ﹤0.01% 4818
2025
Q1 		$128K Buy
+22,650
New +$185K ﹤0.01% 4509

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Raymond James Financial's CADL Position: Q1 2026 in Review

Raymond James Financial increased its Candel Therapeutics (CADL) stake by 21% in Q1 2026, buying an estimated $38.1K and bringing the position to 40,000 shares worth $196K. The position accounts for ﹤0.01% of the portfolio, ranked #4895.

Raymond James Financial first reported a position in CADL in Q1 2025 and has held it in 5 quarters since. 114 funds tracked by Wall St. Rank hold CADL as of Q1 2026.

  • Raymond James Financial held 40,000 shares of Candel Therapeutics worth $196K as of Q1 2026.
  • Raymond James Financial bought 7,000 Candel Therapeutics shares in Q1 2026, an estimated $38.1K.
  • Candel Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #4895 holding.
  • Raymond James Financial first reported a position in Candel Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • 114 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.